Stanford researchers have applied large-scale proteomic platforms to identify biomarkers that can be used to diagnose uveal melanoma and subtype eye tumors according to their gene expression profile (GEP) class or PRAME status.
A team of researchers at Stanford have developed a hydrogel that delivers a scar-reducing focal adhesion kinase inhibitor (FAK-I) to skin grafts and donor sites.
Researchers in the laboratories of Prof. Stanley Cohen and Prof Tzu-Hao Cheng have discovered that Supt4h is a potential therapeutic target for reducing toxicity and restoring the functionality of deleterious proteins in Huntington's (HD) and other polyQ diseases.
Dr. Stanley Cohen and colleagues have identified small molecular compounds that may be useful in the treatment of nucleotide repeat diseases. A well-known nucleotide repeat disorder is Huntington's disease.
Collagen-based hydrogels behave similarly to the native tissue microenvironment, thus are widely used as scaffolds for encapsulating cells or molecules like growth factors. Collagen solution is an injectable liquid until it crosslinks at 37 C and physiological pH.
Researchers from Prof. Karl Deisseroth's laboratory have developed techniques for specifically modulating the activity of excitable cells in vivo. This approach introduces light-responsive proteins to create photo-sensitive cells.
The inventors have developed a light-driven chloride pump (NpHR or Halo) for temporally precise optical inhibition of neural activity with ordinary yellow light.
Temporally precise, noninvasive control of neural circuitry is a long-sought goal of neuroscientists and biomedical engineers. Stanford University researchers in the laboratory of Dr.
The inventors have identified and developed an archaeal light-driven chloride pump (NpHR) from Natronomonas pharaonis for temporally precise optical inhibition of neural activity. NpHR allows either knockout of single action potentials, or sustained blockade of spiking.
Ion channel dysfunctions lead to a wide array of illnesses including epilepsy, cardiac arrhythmia and type II diabetes. However, the number of clinically approved drugs for restoring normal ion channel function is limited.